This is a scarce-capacity and mix-upgrade story, not a heroic multiple story. The upside comes from monetizing
advanced packaging, test and U.S.-located capacity at better utilization and better revenue quality. I assume only a modest
rerating because Amkor still sells execution-heavy manufacturing services, but that is enough for a solid multi-year compounding outcome if Arizona and Korea load well.